Companies
ONC
BeOne Medicines Ltd.
BeOne Medicines Ltd. markets approved oncology and hematology products including BRUKINSA, TEVIMBRA, PARTRUVIX, XGEVA, and KYPROLIS across multiple geographies including the United States and China. The company faces significant regulatory and reimbursement challenges as pricing and coverage policies evolve under new government initiatives in the U.S. and price controls in markets like China, which could materially impact profitability and margins.
$295.27+13.65%1Y
ONC · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 3Metastatic Gastric Adenocarcinoma
Phase 3Gastroesophageal Junction Adenocarcinoma
Phase 3Chronic Lymphocytic Leukemia
Phase 3Advanced Malignancies
Phase 3Advanced Malignancies
Phase 2B-cell Malignancy
Phase 2Relapsed Cancer
Phase 2Refractory Cancer
Phase 2B-cell Lymphoma
Phase 3Chronic Lymphocytic Leukemia
Phase 3Small Lymphocytic Lymphoma
Phase 2Marginal Zone Lymphoma
Phase 2Follicular Lymphoma
Phase 2Non-Hodgkin Lymphoma
Phase 2Waldenström Macroglobulinemia
Phase 2Mantle-cell Lymphoma
Phase 2Diffuse Large B-Cell Lymphoma
Phase 3CLL
Phase 3Advanced Malignancies
Phase 3Advanced Malignancies
Phase 3Metastatic Gastric Adenocarcinoma
Phase 3Gastroesophageal Junction Adenocarcinoma
Phase 3Advanced Malignancies
Phase 3Advanced Malignancies
Phase 2B-cell Malignancy
Phase 2Relapsed Cancer
Phase 2Refractory Cancer
Phase 2B-cell Lymphoma
Phase 3Chronic Lymphocytic Leukemia
Phase 3Small Lymphocytic Lymphoma
Phase 3CLL
Phase 3Advanced Malignancies
Phase 3Advanced Malignancies
Phase 3Advanced Malignancies
Phase 2Waldenstrom Macroglobulinemia
Phase 2Waldenstrom's Macroglobulinemia Recurrent
Phase 2Chronic Lymphocytic Leukemia
Phase 3Mantle-cell Lymphoma
Phase 3B-cell Lymphoma
Phase 2B-cell Malignancy
Phase 2Relapsed Cancer
Phase 2Refractory Cancer
Phase 2Relapsed Refractory Multiple Myeloma
Phase 3Small Lymphocytic Lymphoma
Phase 3CLL
Phase 3Metastatic Gastric Adenocarcinoma
Phase 3Gastroesophageal Junction Adenocarcinoma
Phase 3Advanced Malignancies
Phase 3Advanced Malignancies
Phase 3Advanced Malignancies
Phase 3Advanced Malignancies
Phase 2Waldenstrom Macroglobulinemia
Phase 2Waldenstrom's Macroglobulinemia Recurrent
Phase 2Chronic Lymphocytic Leukemia
Phase 3Mantle-cell Lymphoma
Phase 3B-cell Lymphoma
Phase 2B-cell Malignancy
Phase 2Relapsed Cancer
Phase 2Refractory Cancer
Phase 2/3Primary Membranous Nephropathy
Phase 3CLL
Phase 2/3Primary Membranous Nephropathy
Phase 2Relapsed Refractory Multiple Myeloma
Phase 2Relapsed Refractory Multiple Myeloma
Phase 2Relapsed Refractory Multiple Myeloma
Phase 2B-cell Malignancy
Phase 2Relapsed Cancer
Phase 2Refractory Cancer
Phase 2B-cell Lymphoma
Phase 2B-cell Malignancy
Phase 2Relapsed Cancer
Phase 2Refractory Cancer
Phase 2B-cell Lymphoma
Phase 2Relapsed Refractory Multiple Myeloma
Catalyst Calendar
No catalyst events on record for yet. Check back after the next daily ingest.